TITLE

Sorafenib in Renal Cell Carcinoma: Decision Algorithm

AUTHOR(S)
Vázquez, Sergio; León, Luis; Lázaro, Martín
PUB. DATE
April 2014
SOURCE
Cancer & Chemotherapy Reviews;Apr-Jun2014, Vol. 9 Issue 2, p61
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Molecular-targeted therapy with multikinase inhibitors has been recommended as first-choice therapy in advanced renal cell carcinoma. Sorafenib is a tyrosine kinase inhibitor able to inhibit vascular endothelial growth factor receptors, platelet-derived growth factor receptors, and Raf kinase, interrupting the Ras/Raf/MEK intracellular signaling pathway as well as angiogenesis. Sorafenib demonstrated activity for the treatment of patients with advanced renal cell carcinoma who failed on prior interferon-alpha or interleukin-2 based therapy or who were considered unsuitable for such therapy. Expanded-access studies in Europe and North America showed the safety and efficacy of sorafenib in special populations such as the elderly and those with renal failure and cerebral metastases, as well as patients with no prior therapy. Sorafenib has been used as a second-line comparator arm versus axitinib and temsirolimus, and in the third-line setting against dovitinib. Therefore, when selecting a second-line tyrosine kinase inhibitor, its effectiveness and associated toxicity profile should be considered.
ACCESSION #
99757147

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics